Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Depression 6 Neoplasms 5 Anxiety Disorders 5 Melanoma 2 Depressive Disorder, Major 2 Pain 1 Osteosarcoma 1 Opioid-Related Disorders 1 Neoplasm Metastasis 1 Lymphoma 1 Hospice 1 Hematopoietic and Lymphatic System Neoplasm 1 Endocrine Gland Neoplasms 1 Depressive Disorder 1 Caregiver Distress 1 Carcinoma, Non-Small-Cell Lung 1 Agnosia 1

Interventions

Ropivacaine 2 Magnesium Sulfate 2 Fentanyl 2 trimebutine 3-thiocarbamoylbenzenesulfonate 1 ramosetron 1 Transdermal Patch 1 Tablets 1 Surveys and Questionnaires 1 Psilocybin 1 Pregabalin 1 Nefopam 1 Morphine 1 Lidocaine 1 Levobupivacaine 1 Ketoprofen 1 Ketamine 1 Injections, Subcutaneous 1 High-Energy Shock Waves 1 Control Groups 1 Capsaicin 1 Bupivacaine 1 Botulinum Toxins, Type A 1 Anesthetics, Local 1 Analgesics, Opioid 1 Acetaminophen 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Agnosia × Psilocybin × Clear all

NCT06001749 2025-12-16

Psilocybin in Cancer Pain Study

Dana-Farber Cancer Institute

Phase 2 Recruiting

Agnosia, Opioid-Related Disorders

Data powered by HemOnc (CC BY 4.0) Colophon ⚡